| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc37a2e81be7220b8efdb88f46d09527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41892aff43a006d2004e4104ff31c9e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e40437dddb4da1e093f63a0a7c1f316 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-046 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2003-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2008-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7c096a69d4717fc46edf9b22849b7f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5c1e3d44473a9446da9f29b134b9694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9609b2dae3fd88526079c01303bf751b |
| publicationDate |
2008-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7425217-B2 |
| titleOfInvention |
System and method for inhibiting cellular proliferation with tachykinins |
| abstract |
Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7951193-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005197289-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7833266-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011009334-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8357653-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7691817-B2 |
| priorityDate |
2000-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |